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Background: The risk of inadequate nutrition such as trace elements and vitamin deficiencies is considerable in
postmenopausal women. The aim of this study was to compare trace elements (Zinc, Copper and Magnesium)
concentration in nail, urine and serum among osteoporotic postmenopausal women with control group in Iran.
Methods: Forty eight postmenopausal women aged 36–60 years, were recruited, consisting 30 osteoporotic
patients and 18 healthy controls. Blood, nail and urine concentration of Zinc (Zn), copper (Cu) and magnesium (Mg)
were determined using Inductively Coupled Plasma -Atomic Emission Spectrometry (ICP-AES) method. Their Bone
Mineral Density was measured by Dual X-ray Absorption (DEXA) method.
Results: The urine level of trace elements had significant difference between osteoporotic groups and controls
(p < 0.001). Moreover Mg level significantly differed in serum between two groups (p < 0.04). There was no
statistically significant difference in trace minerals in nail beyond groups.
Conclusion: Our findings indicate that Urine Zn level could be considerable an appropriate marker for bone
absorption, usage of Zn supplements in postmenopausal women may result a beneficial reduction in osteoporotic
risk.
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Osteoporosis is the most common metabolic bone disease
[1]. It is characterized by low bone mass and micro-
architectural deterioration of bone tissue, leading to
enhanced bone fragility and a consequent increase in frac-
ture risk [2]. Osteoporosis is a multi factorial disease and
several factors such as, genetics, gender, age, race, weight,
medical conditions, medication and life style risk factors
are considered to be important determinants of it [3]. The
Iranian Multicenter Osteoporosis Study (IMOS) estimated
that the prevalence of osteoporosis among women older* Correspondence: emrc@sina.tums.ac.ir
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distribution, and reproduction in any mediumthan 50 years is 6 percent, which is less than other coun-
tries such as Canada and Japan [4].
One of the most important modifiable factors in the de-
velopment and maintenance of bone mass is nutrition [5].
Adequate nutrition plays a major role in the prevention
and treatment of osteoporosis [6]. In recent years, there
has been a resurgence of interest in studies concerning the
role of elements in the development and maintenance of
the skeleton [7].
Zinc (Zn) is an essential mineral that is a component of
more than 200 enzymes and is known as to be necessary
for normal collagen synthesis and mineralization of bone
[8]. Copper (Cu), a cofactor for lysyl oxidase, is required in
the cross-linking of collagen and elation. Cu deficiency
causes inhibition of bone growth and osteoporosis [9].
The other element, Magnesium (Mg) appears to be im-
portant in bone cell activity. It is shown to be mitogenicntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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inhibition, in vitro [10].
The growths of nails, and their matrix components,
are influenced by several physiological, pathological, and
environmental factors [11]. Because of the slow rate of
nail growth, the elemental composition of the nail is also
expected to be affected by transient factors controlling
serum components [12]. The mineral components of
nail clippings may therefore reflect the long-term pat-
terns of mineral metabolism such as Hypercreatinemia,
Hyperthyroidism and Iron Deficiency Anemia [13,14].
To understand the status of elements on postmeno-
pausal women with osteoporosis, we have investigated
the Zn, Cu and Mg Cu levels in postmenopausal women
with osteoporosis and without osteoporosis.
Method
In this case–control study (May 2008 to may 2009) forty
eight postmenopausal women aged 36–60 years, ac-
cording to Bone Mineral Density (BMD) divided into
two groups 30 Postmenopausal Osteoporotic women
(case) (T score > −2.5) and 18 non-Osteoporotic post-
menopausal women (control) (T score < −1.0) [11]. They
were recruited among patients who applied to outpatient
osteoporosis clinic of Tehran University of Medical
Sciences (Dr Shariati Hospital). All the postmenopausal
women who had passed one year of their last menstrual
period were included in the study. Exclusion criteria were
as follows:
1. Arthritis rheumatoid, Diabetes mellitus, Systemic
lupus erythematosus, Hypo or hyperthyroidism,
Hypo or hyperparathyroidism, Hepatic failure, Renal
failure, Cirrhosis, Cushing’s syndrome, Adrenal
failure, Cancers.
2. Menstrual disorders as initial menstrual cycle after 18
and permanent discontinuation before 40 years old.
3. Smoking (more than half a packet per day),
addiction and the history of alcohol consumption for
more than 5 years.
4. Professional sports, past history of lumbar fractures,
fractures because of simple falls, spinal deformity,
and seeking admission in the last two weeks or
complete best rest for 3 consecutive months.
5. Previous Usage of Estrogen Progesterone,
Furosemide, Antiepileptic drugs, Corticosteroids,
Heparin, Thiazide and any trace mineral
Supplements.
The study was performed in accordance with the Decla-
ration of Helsinki and subsequent revisions and approved
by ethics committee at Endocrinology and Metabolism
Research Centre (EMRC). Informed consent was sought and
obtained from individuals before enrollment into the study.Having received the letters of consent, the related ques-
tionnaires were completed and clinical examinations such
as height and weight were carried out. The weight of all
participants with minimum of clothes by using digital scales
(Seca) with an accuracy of 0.1 (kg) was measured. Height
was measured using a wall stadiometer (precision 5 mm)
with the patient standing upright and without shoes. The
body mass index (BMI) was calculated by dividing subject’s
weight (kg) by the square of their height (m2). The baseline
information of food intake was collected by using a 24-hour
recall method on three consecutive days.
BMD was measured by DXA using Lunar DPX-MD de-
vice (Lunar Corporation, Madison, Wisconsin, 53713.
USA). The DXA device was calibrated daily and weekly by
using appropriated phantoms methods. To assess BMD,
second to fourth lumbar spine and from the femur bone
(neck, trochanter and the whole femur), bone density was
calculated based on gr/cm2.
Blood and morning second void urine samples were col-
lected after an overnight fast; precautions were taken to
avoid contamination. Serum PTH, Vit D, Mg, Zn, Cu,
ALT, AST, Alb, Cr, Ca, P, and TSH and urine, Zn, Cu and
Mg were collected in the metal free plastic tubes. Toe nail
clippings from all 10 toes were collected within 8 weeks of
inclusion in the study and were stored in small plastic bags
at room temperature. Solid sample of nail was washed
immediately with distilled water and then alcohol dried
and stored. The sufficient amounts of nail samples were
weighed carefully and transfer in to a beaker and added
10 ml of concentrated nitric acid. Then, the solutions were
heated for complete digestion. The resulted solution di-
luted in a volumetric flask with distilled water. Certain
amount of blood and urine samples were also mixed with
concentrated nitric acid to remove interfering of organic
compounds, the resulted solution were then centrifuged.
Inductively Coupled Plasma Atomic Emission Spec-
trometer (ICP-AES) has become the most appropriate
technique for trace element determination [12]. A Varian
ICP-AES (model: VISTA-MPX) was used for analysis.
The amount of trace elements of each samples (serum,
urine and nail) were measured by ICP-AES instrument
using calibration method. This method was based on
special software to calculate the numerical calculation
analyze signal and reduce noise. In current method all
the measurement done by continues cycle voltmeter.
This means that in specified temperature range of Cyclic
voltammeter (CV) wave potential is applied to electrode
and provided number frequency that can shows any
changes in flow produced with electrode.
There are no any cutoff for trace elements concentration
in Iran, therefore we used the cutoffs’ which was deter-
mined in similar articles. Cutoff for plasma Zn was 75–
120 microgram/dl, and for plasma Cu and plasma Mg
were considered 70–140 and 19.5-2.33 microgram/dl
Table 2 Comparison of Cu, Mg, and Zn in plasma, urine,
and nail between osteoporotic and control groups
Trace elements
Control group Osteoporotic
P - value
Mean (SD) Mean (SD)
Serum
Cu [ppm] 1.12 (0.53) 0.98 (0.43) NS
Mg [ppm] 19.80 (8.23) 15.08 (4.89) P = 0.04
Zn [ppm] 0.84 (0.43) 0.68 (0.23) NS
Nail
Cu [ppm] 7.84 (10.71) 6.91(8.15) NS
Mg [ppm] 87.88 (78.21) 90.76 (97.30) NS
Zn [ppm] 81.60 (86.14) 82.57 (103.07) NS
Urine
Cu [μg/g] 0.049 (0.013) 0.038 (0.024) NS
Mg [μg/g] 5.80 (1.36) 6.56 (2.24) NS
Zn [μg/g] 0.51(0.35) 1.72 (1.49) P< 0.001
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using enzymatic method (BioLif 24i, Premium, Tokyo,
Boeki medical system, Japan) and Radioimmunoassay for
Vit D (IDS kits, UK), PTH (Diasorin kits, USA) and TSH
(Automatic Gama Counter, Wizard of Swiss).
The measurement of Zn, Cu and Mg in diets was done
by modified software, Food Processing 2 (FP2).
The significance of difference in trace elements level in
samples between two groups was tested using independ-
ent t-test analysis. Association between variables was de-
termined using the Pearson’s correlation analysis on
Microsoft excel and SPSS software version 13.0 (California
Inc.). A two sided P-value <0.05 was considered statisti-
cally significant for the t-test and Pearson correlation
analysis.Result
Table 1 shows the baseline characteristics and biochem-
ical findings of two groups based on BMD. There was
no statistically significant difference between two groups
in the characteristics.
Table 2 shows the levels of trace elements in serum,
urine and nail in two groups. The serum Mg level was
significantly less in cases (P = 0.04) than in controls. The
urine Zn level between osteoporotic and control group
was significantly different (P < 0.001).
The significant positive correlation between urine Cu
and serum TSH (p = 0.02 r =0.37). There was significantly
negative correlation between PTH and urine Zn (p = 0.00,
r = −0.53), (p = 0.01, r = −0.47).Table 1 Comparison of baseline characteristics between
osteoporotic and control groups
Variable
Osteoporotic
group
Control
group p- value
Mean (SD) Mean (SD)
Age [years] 58.4 (6.4) 57.6 (4.7) NS
BMI [kg/m2] 28.4 (4.5) 27.7 (4.3) NS
Menopausal age [years] 51.6 (2.4) 50.8 (3.2) NS
AST [Iu/l] 22.86 (9.86) 28.18 (22.14) NS
ALT(Iu/l) 11.90 (5.67) 15.56 (13.08) NS
Alp [Iu/l] 176.03(115.20) 187.94 (130.10) NS
Ca [mg/dl] 8.7 (0.38) 9.09 (0.39) NS
P [mg/dl] 3.76 (0.40) 3.95 (0.59) NS
Vit D [ng/mg] 29.89 (31.70) 12.56 (14.99) P = 0.04
PTH [pg/ml] 65.57 (35.91) 69.43 (24.55) NS
Alb [mg/dl] 5.01(0.31) 4.90 (0.38) NS
Cr [mg/dl] 0.91(0.21) 0.94 (0.10) NS
BMI body mass index, PTH paratormone hormone, Alb albumin, P phosphorus,
Ca calcium, ALT alanine amino transpherase, AST aspartate amino
transpherase, Vit vitamine, Alb albumin, Alp alkaline phosphatase. The level of
vitamin D in osteoporotic group was higher than control group.There was no correlation between case and control
groups in the nails’ samples.
Discussion
Some studies have shown the effect of nutrition on bone
turnover and osteoporosis. In this study we investigate Zn,
Cu and Mg in serum, urine and content of nail in post
menopausal women that referred to clinic of osteoporosis -
Shariati Hospital in Tehran University and divided them in
two groups of osteoporotic and non -osteoporotic women.
Zn is involved in bone metabolism is based on observa-
tions that osteoporotic patients have increased urinary Zn
losses [15]. Urine Zn excretion in osteoporotic patients was
significantly lower than control group and there was not
any meaningful difference in serum Zn in two groups. Ac-
tually bone demineralization in osteoporosis could cause
high excretion of trace minerals, although in study group
the level of Zn in plasma was higher than control group in
our study. Similar to our study, Reginster et al. [16] re-
ported no significant difference in Zn and Cu plasma levels
between postmenopausal women with osteoporosis and
non-osteoporotic subjects. Relea et al. [8] have reported
that the urine clearance of Zn in postmenopausal women
was higher than in the normal women. In contrast, several
studies found that serum Zn and Cu levels were lower
among patients with postmenopausal osteoporosis than
controls [17-19]. A relationship exists between the excre-
tion of Zn in 24-hour urine and the appearance of osteo-
porosis, and the urinary Zn/creatinine relationship is a
factor to take in mind in the osteoporosis [20,21].
Regarding the relationship between serum [22-24] and
urine Zn, it seems that higher serum PTH in osteopor-
otic group comparing to normal amounts of PTH, rising
Zn urinary excretion. The lack of significant difference
in serum Zn between case and control groups can be
attributed to higher than normal PTH concentration. In
present study in consistency with other studies, urinary
Zn levels in control group were higher than cases.
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are highly indicative of the value of this parameter as
biochemical markers of bone resorption for the diagno-
sis of osteoporosis [15,20].
We found that there is no significant difference in
serum level of Zn in two groups and it may be because
of having small population size. Several studies reported
that serum Zn and Cu levels were lower among patients
with postmenopausal osteoporosis than controls [25-27].
In contrast, Reginster et al. [16] significant difference in
Zn and Cu plasma levels between two groups. Two stud-
ies [28,29] found that serum Zn level was lower among
the postmenopausal osteoporotic women than controls.
We found similar Cu levels in osteoporotic and non-
osteoporotic postmenopausal women. Other studies [13,14]
have revealed that Cu deficiency resulted in postmeno-
pausal osteoporosis. In a study by Conlan et al. [15] elderly
patients with femoral neck fractures were found to have
significantly lower serum Cu levels than controls adjusted
for age and sex. Although the Cu content of bone was
negatively correlated with bone Ca, bone density and colla-
gen content in aging mice [16], bone Cu levels in human
subjects with osteoporosis were found to be the same or
slightly higher than normal individuals of the same age
[10,17].
Tranquilli et al. [30] reported that the uptake of Mg, P,
and Cu are low in women with postmenopausal osteopor-
osis as compared to the control group and that this corre-
lated with bone mineral content. Cross-sectional studies
demonstrated a strong correlation between low BMD, low
dietary Ca intake, and serum Cu levels in postmenopausal
women [19].
Our study showed that the contents of serum Mg in
osteoporotic patients is significantly lower than control
group. Mg appears to be important in bone cell activity
and contributes macro element quantities to bone ash
and is essential for appropriate calcium metabolism, af-
fecting calcium balance. Trabecular but not cortical
bone was improved with per oral Mg in a small group of
postmenopausal osteoporotic women [31,32].
Carpenter [33] demonstrated that Mg deficiency has
an effect on osteocalcin synthesis and secretion and
that this resulted in decreased osteocalcin synthesis.
Two studies [20,21] reported that serum Mg in osteo-
porotic women were significantly lower than the value
in matched normal subjects. Conversely, Steidl et al.
[17] found a significant decrease in erythrocyte Mg
content in patients with postmenopausal and senile
osteoporosis but not in their serum levels.
Gur et al. [34] reported that Mg levels in serum were
lower among patients with postmenopausal osteoporosis
than the controls.
The level of Cu and Mg secretion in urine did not
have any significant difference in two groups. Urine is aclinical specimen often used in medical diagnostics for
monitoring of elements concentrations and osteoporosis.
Basing on Dlugaszek study, they concluded that BMD
and age of postmenopausal osteoporosis may impact
greatly on the elemental status of 24-h urine [35]. The
other research showed that Mg levels in 24-hour urinary
excretion of Mg were increased in the postmenopausal
women compared with the premenopausal women and
postmenopausal hypermagnesiuria probably originates
from increased intestinal magnesium absorption [36].
Schlemmer reported [37] that Ca supplementation in-
fluences the urinary excretion of Mg after menopause.
Two studies [38,39] found that women with osteopor-
osis displayed Mg deficiency and a highly significant
correlation existed between increased Mg urinary excre-
tion and low serum Ca.
There are a little evidence related to association be-
tween the contents of trace elements in nail and bone
densitometry in postmenopausal women.
In our research there was no correlation between case
and control groups in the nail samples.
Concentration of Zn in fingernails was significantly
but negatively correlated with bone mineral density
and a significant positive correlation of Ca/Zn ratio of
fingernails was observed with bone mineral density.
The content of Zn in nails may be affected by alter-
ations in bone Zn status and a potential application of
nail Zn level or Ca/Zn ratio as an indicator of post-
menopausal and senile osteoporosis.
Three studies [25-27] in postmenopausal women have
been shown lower nail Ca concentrations than in pre-
menopausal women. Their BMD status showed a sig-
nificant positive correlation with nail Ca content. The
demonstration of an inverse relationship between nail
Ca and Mg content may contribute to the understand-
ing of the role of these minerals in the development of
osteoporosis [28].
An Irish study demonstrated that nail testing as such a
method is inconclusive but these preliminary findings sug-
gest that changes in bone proteins seen in osteoporosis
may be mirrored by changes related to structural proteins
[40,41].
In Table 1 level of vitamin D in osteoporotic group
was higher than control group.
We had limitation in our study: 1. this study is a single
center study in osteoporosis clinic of Tehran University
of Medical Sciences (Dr Shariati Hospital) 1.not all of
our studied patients comes in repeated follow ups, 2.
Delay in result of laboratory tests 3. It’s difficult to find
the suitable samples.
Some studies have shown that all patients with osteo-
porosis treated with vitamin D and calcium are serum
levels of calcium and vitamin D than their peers in non-
osteoporotic, as shown in our study [5,40].
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Our findings indicate that Urine Zn level could be consid-
erable an appropriate marker for bone absorption, usage
of Zn supplements in postmenopausal women may result
a beneficial reduction in osteoporotic risk.
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